Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Pires da Silva I, et al. Among authors: serra bellver p. Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989557
Sequential immunotherapy regimens-expect the unexpected.
Serra-Bellver P, Valpione S, Lorigan P. Serra-Bellver P, et al. Lancet Oncol. 2016 Jul;17(7):854-855. doi: 10.1016/S1470-2045(16)30198-X. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269742 No abstract available.
The role of nivolumab in melanoma.
Gomes F, Serra-Bellver P, Lorigan P. Gomes F, et al. Among authors: serra bellver p. Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12. Future Oncol. 2018. PMID: 29328782 Review.
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Zimmer L, Trojaniello C, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Menzies AM, Long GV. da Silva IP, et al. Among authors: serra bellver p. Lancet Oncol. 2021 Aug;22(8):e343-e344. doi: 10.1016/S1470-2045(21)00419-8. Lancet Oncol. 2021. PMID: 34339647 No abstract available.
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. Pires da Silva I, et al. Among authors: serra bellver p. J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. J Clin Oncol. 2022. PMID: 35143285
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Lee KA, et al. Among authors: serra bellver p. Nat Med. 2022 Mar;28(3):535-544. doi: 10.1038/s41591-022-01695-5. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228751 Free PMC article.
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Serra-Bellver P, et al. Eur J Cancer. 2022 Nov;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub 2022 Oct 7. Eur J Cancer. 2022. PMID: 36215945 Free article.
Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.
Valpione S, Campana LG, Weightman J, Salih Z, Galvani E, Mundra PA, De Rosa F, Gupta A, Serra-Bellver P, Lorigan P, Germetaki T, Dynowski M, Kitcatt S, Sahoo S, Lee D, Dhomen N, Lord G, Marais R. Valpione S, et al. Among authors: serra bellver p. Eur J Cancer. 2022 Dec;177:164-174. doi: 10.1016/j.ejca.2022.09.022. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36347135 Free article.
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, Smit LM, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Spector TD, Bataille V, Segata N, Hospers GAP, Weersma RK. Björk JR, et al. Among authors: serra bellver p. Nat Med. 2024 Mar;30(3):785-796. doi: 10.1038/s41591-024-02803-3. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365950 Free PMC article.
11 results